Three things we took away from attending Drug Discovery Chemistry in 2024

April 10, 2024 NanoTemper Technologies

Drug Discovery Chemistry is an annual event that focuses solely on early drug discovery, where scientists from around the world gather to showcase their research and participate in thoughtful discussions. This year the conference recorded its highest attendance, with over 900 attendees, which made for an excellent environment to network and learn about the future of drug discovery.

 
Here are three takeaways we got from attending this year’s conference:
 

    1. Artificial Intelligence (AI) and Machine Learning (ML) must overcome crucial challenges to drive decisions in early drug discovery

    AI and ML are revolutionizing many fields, but a few critical challenges must be addressed before they can reach their full potential for drug discovery. A lack of standardization for data generation and collection, data privacy concerns, and the complexity of disease progression make it challenging to feed AI models relevant data. Increasing computational power will help scientists tackle the complexity of the data, but it won’t help them make confident decisions from bad data.

 

    2. Collaborative breakout discussions offer a great opportunity for scientists to meet and share ideas with other experts in early drug discovery

    The round-table and interactive panel discussions offered a two-way approach to exchange knowledge on topics like developing tumor-selective degraders, FBDD against RNA targets, and DEL for degrader discovery. These discussions provided a great space for scientists to share ideas, discuss their workflows, hear how others deal with challenges, and lay the groundwork for future collaborations in an informal and relaxed environment. This kind of open communication helps foster the innovation needed to create a world where every disease is treatable.

 

 
What conferences are you attending next? Here are a few you shouldn’t miss if you’re interested in keeping up with the latest developments in targeted protein degradation or biologics.

Previous Article
Direct comparison of binding affinities from Spectral Shift and SPR for biotinylated targets
Direct comparison of binding affinities from Spectral Shift and SPR for biotinylated targets

Up next
Screening for p38 ligands: From assay optimization to lead validation in 2 days
Screening for p38 ligands: From assay optimization to lead validation in 2 days

Dianthus is a biophysical screening instrument that uses Spectral Shift technology to measure molecular int...

Ready to tackle your challenging affinity screening?

Discover tools you can use

Learn more